Pacira BioSciences (PCRX) Operating Expenses (2010 - 2026)

Pacira BioSciences' Operating Expenses history runs 17 years deep, the most recent figure standing at $170.5 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 2.12% year-over-year to $170.5 million; the TTM figure through Mar 2026 stood at $710.8 million (down 9.73% YoY), while the FY2025 annual figure was $707.2 million, down 8.67% from the prior year.
• Operating Expenses was $170.5 million for Q1 2026 at Pacira BioSciences, down from $194.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $308.1 million in Q3 2024 to a low of $129.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $167.4 million across 5 years, with a median of $162.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 110.73% in 2024, then tumbled 43.8% in 2025.
• A 5-year view of Operating Expenses shows it stood at $181.8 million in 2022, then dropped by 18.57% to $148.1 million in 2023, then grew by 9.77% to $162.5 million in 2024, then advanced by 19.68% to $194.5 million in 2025, then declined by 12.37% to $170.5 million in 2026.
• The last three Operating Expenses figures came in at $170.5 million (Q1 2026), $194.5 million (Q4 2025), and $173.2 million (Q3 2025), per Business Quant data.